South Korea · Delayed Price · Currency is KRW High Tech Pharm Statistics
Total Valuation
High Tech Pharm has a market cap or net worth of KRW 130.04 billion. The enterprise value is 117.23 billion.
| Market Cap | 130.04B |
| Enterprise Value | 117.23B |
Important Dates
The last earnings date was Wednesday, November 12, 2025.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
High Tech Pharm has 10.63 million shares outstanding.
| Current Share Class | 10.63M |
| Shares Outstanding | 10.63M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.61% |
| Owned by Institutions (%) | 0.36% |
| Float | 5.83M |
Valuation Ratios
The trailing PE ratio is 10.85.
| PE Ratio | 10.85 |
| Forward PE | n/a |
| PS Ratio | 1.72 |
| PB Ratio | 1.02 |
| P/TBV Ratio | 1.02 |
| P/FCF Ratio | 7.09 |
| P/OCF Ratio | 6.33 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.57, with an EV/FCF ratio of 6.39.
| EV / Earnings | 9.79 |
| EV / Sales | 1.55 |
| EV / EBITDA | 6.57 |
| EV / EBIT | 9.39 |
| EV / FCF | 6.39 |
Financial Position
The company has a current ratio of 5.56, with a Debt / Equity ratio of 0.00.
| Current Ratio | 5.56 |
| Quick Ratio | 2.44 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | 0.00 |
| Interest Coverage | 37.12 |
Financial Efficiency
Return on equity (ROE) is 9.85% and return on invested capital (ROIC) is 6.09%.
| Return on Equity (ROE) | 9.85% |
| Return on Assets (ROA) | 5.59% |
| Return on Invested Capital (ROIC) | 6.09% |
| Return on Capital Employed (ROCE) | 9.78% |
| Revenue Per Employee | 1.16B |
| Profits Per Employee | 184.31M |
| Employee Count | 65 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.70 |
Taxes
In the past 12 months, High Tech Pharm has paid 2.68 billion in taxes.
| Income Tax | 2.68B |
| Effective Tax Rate | 18.26% |
Stock Price Statistics
The stock price has decreased by -11.12% in the last 52 weeks. The beta is 0.76, so High Tech Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | -11.12% |
| 50-Day Moving Average | 12,677.00 |
| 200-Day Moving Average | 13,153.50 |
| Relative Strength Index (RSI) | 48.34 |
| Average Volume (20 Days) | 22,789 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, High Tech Pharm had revenue of KRW 75.60 billion and earned 11.98 billion in profits.
| Revenue | 75.60B |
| Gross Profit | 16.36B |
| Operating Income | 12.48B |
| Pretax Income | 14.66B |
| Net Income | 11.98B |
| EBITDA | 17.84B |
| EBIT | 12.48B |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 12.86 billion in cash and 40.02 million in debt, giving a net cash position of 12.82 billion or 1,205.21 per share.
| Cash & Cash Equivalents | 12.86B |
| Total Debt | 40.02M |
| Net Cash | 12.82B |
| Net Cash Per Share | 1,205.21 |
| Equity (Book Value) | 126.99B |
| Book Value Per Share | n/a |
| Working Capital | 54.21B |
Cash Flow
In the last 12 months, operating cash flow was 20.54 billion and capital expenditures -2.21 billion, giving a free cash flow of 18.33 billion.
| Operating Cash Flow | 20.54B |
| Capital Expenditures | -2.21B |
| Free Cash Flow | 18.33B |
| FCF Per Share | 1,724.01 |
Margins
Gross margin is 21.65%, with operating and profit margins of 16.51% and 15.85%.
| Gross Margin | 21.65% |
| Operating Margin | 16.51% |
| Pretax Margin | 19.39% |
| Profit Margin | 15.85% |
| EBITDA Margin | 23.60% |
| EBIT Margin | 16.51% |
| FCF Margin | 24.25% |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 0.82%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 0.82% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 8.88% |
| Buyback Yield | n/a |
| Shareholder Yield | 0.82% |
| Earnings Yield | 9.21% |
| FCF Yield | 14.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 27, 2023. It was a forward split with a ratio of 1.5.
| Last Split Date | Dec 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
High Tech Pharm has an Altman Z-Score of 9.28 and a Piotroski F-Score of 5.
| Altman Z-Score | 9.28 |
| Piotroski F-Score | 5 |